Zentalis Pharmaceuticals Inc (ZNTL) | |||
---|---|---|---|
15.76 0.57 (3.75%) | 03-28 16:00 | ||
Open: | 15.28 | Pre. Close: | 15.19 |
High: | 16.075 | Low: | 15.22 |
Volume: | 579,811 | Market Cap: | 1,118(M) |
Stock Technical Analysis | |
---|---|
Overall: | |
Target: | Six months: 21.11 One year: 24.65 |
Support: | Support1: 15.03 Support2: 13.15 |
Resistance: | Resistance1: 18.07 Resistance2: 21.11 |
Pivot: | 14.36 |
Moving Averages: | MA(5): 14.45 MA(20): 14.44 MA(100): 13.25 MA(250): 19.45 |
MACD: | MACD(12,26): 0.25 Signal(12,26,9): 0.19 |
%K %D: | %K(14,3): 66.19 %D(3): 43.64 |
RSI: | RSI(14): 62.87 |
52-Week: | High: 31.46 Low: 9.56 Change(%): -5.2 |
Average Vol(K): | 3-Month: 824 10-Days: 742 |
Prices Prediction (Update @5:00pm) | ||
---|---|---|
If tomorrow: | Open lower | Open higher |
High: | 16.104 - 16.169 | 16.169 - 16.236 |
Low: | 15.066 - 15.131 | 15.131 - 15.198 |
Close: | 15.651 - 15.766 | 15.766 - 15.886 |
Price, MAs and Bollinger Bands |
---|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ZNTL ] has closed below upper band by 0.7%. Bollinger Bands are 36.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
Company profile |
---|
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York. |
Stock chart |
---|
Financial Analysis | |
---|---|
Price to Book Value: | Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
Price to Earnings: | Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
Discounted cash flow: | Underperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
Return on Assets: | Underperform |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
Return on Equity: | Underperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
Debt to Equity: | Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Stock Basics & Statistics | |
---|---|
Exchange: NASDAQ Global Market | |
Sector: Healthcare | |
Industry: Biotechnology | |
Shares Out. (M) | 70.96 |
Shares Float (M) | 50.39 |
% Held by Insiders | 4.22 |
% Held by Institutions | 114.89 |
Shares Short (K) | 14560 |
Shares Short Prior Month (K) | 13670 |
Stock Financials | |
---|---|
EPS | -4.470 |
Book Value (p.s.) | 6.180 |
Profit Margin | |
Operating Margin | |
Return on Assets (ttm) | -28.5 |
Return on Equity (ttm) | -67.1 |
Qtrly Rev. Growth | |
Gross Profit (p.s.) | |
Sales Per Share | |
EBITDA (p.s.) | -3.489 |
Qtrly Earnings Growth | |
Operating Cash Flow (M) | -207.82 |
Levered Free Cash Flow (M) | -86.97 |
Stock Valuation | |
---|---|
PE Ratio | -3.53 |
PEG Ratio | |
Price to Book value | 2.55 |
Price to Sales | |
Price to Cash Flow | -5.38 |
Stock Dividends | |
---|---|
Dividend | |
Dividend Yield | |
Dividend Growth |